ArticleCancer2017
Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme.
Article in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Drug-herb combination therapy in cancer management.Molecular biology reports · 2022Pooled it
- Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation.BioMed research international · 2019Pooled it
- Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.Drug delivery and translational research · 2024Review
- Colorectal Cancer Survival in German-Danish Border Regions-A Registry-Based Cohort Study.Cancers · 2023Article
- National oncofertility registries around the globe: a pilot survey.Frontiers in endocrinology · 2023Article
- Protective Effect of Polysaccharides Extracted fromInternational journal of molecular sciences · 2021Article
- Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?British journal of cancer · 2021Review
- Characterization of the Golgi scaffold protein PAQR3, and its role in tumor suppression and metabolic pathway compartmentalization.Cancer management and research · 2020Review
- Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.Lancet (London, England) · 2018Article
- Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences.Frontiers in pharmacology · 2018Review
- Colon cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.Cancer · 2017Article
- The essential role of population-based cancer survival in cancer control in the United States.Cancer · 2017Article
- Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.Cancer · 2017Article
- Population-based cancer survival (2001 to 2009) in the United States: Findings from the CONCORD-2 study.Cancer · 2017Article
- Pathological Complete Response by S-1 Chemotherapy in Advanced Gastric Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
CONCORD is a programme for the global surveillance of cancer survival. In 2015, the second cycle of the program (CONCORD-2) established long-term surveillance of cancer survival worldwide, for the first time, in the largest cancer survival study published to date. CONCORD-2 provided cancer survival trends for 25,676,887 patients diagnosed during the 15-year period between 1995 and 2009 with 1 of 10 common cancers that collectively represented 63% of the global cancer burden in 2009. Herein, the authors summarize the past, describe the present, and outline the future of the CONCORD programme. They discuss the difference between population-based studies and clinical trials, and review the importance of international comparisons of population-based cancer survival. This study will focus on the United States. The authors explain why population-based survival estimates are crucial for driving effective cancer control strategies to reduce the wide and persistent disparities in cancer survival between white and black patients, which are likely to be attributable to differences in access to early diagnosis and optimal treatment. Cancer 2017;123:4977-81. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.